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Abstract
The pathologic features of sickle cell disease had been known in the past to be as a result of red cell abnormality
leading to vascular occlusion, haemolysis and consequent anaemia. Recent knowledge has revealed numerous
pathogenetic pathways involving leukocytes, platelets and the vascular endothelium. Complex interactions between
the inflammatory cytokines and the membrane lipids in sickle cell present several pathogenetic processes affecting
disease severity. The mechanisms of membrane fluidity, aggregation, adhesion and inflammation are strongly
associated with membrane lipid constitution. The omega -3 fatty acids via incorporation into the lipid membrane
have been found to play a central role in suppressing inflammation in several disease processes. Variations in
disease severity have been shown to correspond with levels of fatty acid desaturases involved in the synthesis of
these fatty acids. The genes coding for these substances can also be manipulated to achieve a favorable outcome
and may provide several possible therapeutic and prophylactic access points This review aims at exploring these
delicate interactions and proffering possible targets to ameliorate disease features. The information and referenced
publications quoted in this review were obtained from the PubMed Central database, using the search keywords;
inflammation, sickle cell, fatty acids and cytokines.
Keywords: Membrane lipids; Sickle cell disease; Inflammation;
Omega-3 fatty acids; Cytokines; Fatty acid desaturases
Introduction
Sickle cell disease is an inherited disorder in which the mutant
globin gene produces a less efficient haemoglobin molecule, causing
depreciation in the resilience and flexibility of the red cells. Recent
advances have unearthed several other effects of this supposed mutant
globin gene. These effects are now known to include increased
expression and binding of the cellular adhesion molecules to ligands
on the vascular endothelium [1] a process similar to what is observed
during inflammation [2]. This process involves the neutrophils,
monocytes, lymphocytes and platelets as well as the reticulocytes and
red cells. The background inflammatory process tends to be
exacerbated during episodes of vaso-occlusion and has been proposed
to actually initiate them. Inflammation is regarded as the response of
living tissue to any form of assault. This response has both vascular
and cellular components, with a myriad of chemical interactions
mediating the process.
All cells are bound by a membrane considered to be the ‘barrier of
life’, as it is a structure that isolates living cells from their surroundings
[3]. One of the main components of all cellular membranes in all living
cells, are phospholipids, which make up over 40% of the cell
membrane bi-layer. This phospholipid bi-layer, with its interspersed
transmembrane proteins acts as receptors of ligands. The
asymmetrical distribution of membrane lipids in this phospholipid
layer is important in the integrity and survival of most cells. In sickle
cell anaemia, there exists an alteration in the distribution of membrane
lipids, with exposure of phosphatidyl serine (PS) in some red cells in
circulation [4]. This distorts the membrane and consequently exposes
and activates cell adhesion receptors as well as the binding sites of
certain enzymes like promthrombinase [5]. It also initiates apoptosis
of red cells and its removal by the splenic macrophages. The
concentration of the membrane lipids differs across various locations
on the membrane, with some regions showing increased concentration
of certain fatty acids. These areas are known as “rafts” or “micro-
domains”.
The Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA)
and docosapentaenoic acid (DHA), have been observed to have anti-
inflammatory effects. Dietary omega-3 fatty acids are easily
incorporated to a large extent into the cell membrane lipids and thus
influence the composition of the rafts. The mechanisms by which
these poly-unsaturated fatty acids carry out these functions are not
completely understood. However, recent studies have shown that
intake of ω-3 fatty acids decreases levels of C reactive proteins (CRP),
IL-6 and tumor necrosis factors (TNF-α) [6]. These actions are
hypothesized to be effected mainly via regulations of the transcription
factors; nuclear factor κ and peroxisome proliferator activated
receptor. Other inflammatory markers which are reduced such as;
monocytes chemo-attractant protein 1 (MCP-1), intercellular
adhesion molecule 1 (ICAM-1) and lipoprotein-associated
phospholipase A2 (LpPLA-2), also play important roles in increasing
oxidative stress [7].
The rate limiting enzymes in the production of these fatty acids are
the Δ-3 and Δ-6 fatty acid desaturases. The depreciation in activity of
these enzymes may be responsible for the depletion of the PUFAs in
sickle cell disease (SCD) patients, which occurs to a greater extent in
those with severe disease. Protein synthesis is consequent upon DNA
transcription and any mutation in genes coding for these enzymes will
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invariably affect these function. This review aims to explore the
inflammatory pathways involved in SCD as well as the impact of the
PUFAs, desaturases and their complex interactions with regards to the
myriad of phenotypic presentation observed. The review also focuses
on the background genetic variations with regards to FADs activity
that may be responsible for these observed phenotypic differences as
well as suggest possible therapeutic implications.
Inflammatory proteins and the role of membrane lipids
The red cell membrane is made of a phospholipid bi-layer and the
underlying structural protein scaffolding lattice arranged in the format
regarded as the vertical and horizontal associations. The membrane
phospholipids are made up of a polar head and a non-polar fatty acid
tail. There are proteins embedded in this bi-layer that tether them to
the underlying protein lattice. The lipids move rapidly within this bi-
layer and the areas where a high concentration of these lipids and
proteins occur are called ‘micro-domains’ or rafts. [8]. The lipid
contents of these micro-domains to some extent affect the function of
the membrane proteins/ receptors embedded in them [9,10]. These
rafts which take part in signal transduction are rich in sphingomyelin,
cholesterol and saturated glycerol phospholipids [10]. Certain dietary
lipids are easily incorporated into the membrane and reduction in
membrane cholesterol content tends to cause dissolution of these rafts
[11,12].
There also exists an active exchange of lipids between the inner and
outer leaves of the bi-layer, this is not random and is controlled by
certain proteins in the membrane. Sphingomyelin (SM) and
phosphatidyl choline (PC) – the choline containing phospholipids, are
more abundant on the outer layer, while phosphatidyl ethanolamine
(PE) and phosphatidyl serine (PS) predominate on the inner layer.
This balance is maintained by the ATP- dependent membrane
transporter called ‘flippase’, which is a Mg2+-ATPase bound to the
membrane [13]. Recently the enzyme amino-phospholipase
translocase has also been discovered to be important in the
maintenance of the lipid distribution [14]. This dynamic balance is
necessary for the optimal functioning and survival of most eukaryotic
cells.
The phospholipids in the cellular membrane contain fatty acids
(FA), and the type of diet an individual consume will directly
determine the type of FA (saturated or un-saturated) that will be
incorporated into the phospholipid bi-layer, and consequently will
define the ‘structural integrity’ and physical characteristics of the
cellular membrane [3,15, 16]. The lipid composition of the cellular
membrane will therefore, govern the effectiveness of its fluidity and
hence its membrane fluidity index (MFI) [15-17]. The PUFA’s (EPA
and DHA) have been exhibited in many studies to increase the MFI
and thus create a peculiar environment for the membrane proteins-
transporters, ion channels and receptors and by doing this influence
their activity. The physical state of the membrane needs to be
optimally balanced in terms of fluidity [16] in order for cells to carry
out their regular functions and activities maximally. In addition, ideal
MF will decrease the cells susceptibility to damage and death
significantly[3,15]. These areas of the lipid membrane bi-layer, rich in
cholesterol, sphingomyelin and saturated glycerol phospholipids are
called rafts or micro-domains. Apart from their membrane function
these rafts are also known to influence intra-cellular signaling
pathways, [8,18]thus affecting gene expression via their action on
transcription factors [19,20]. These fatty acids are known to effect
these actions by acting on transcription factors; nuclear factor κ,
binding protein for the sterol regulatory element [21] and peroxisome
proliferator activator receptor (PPAR) α and γ [22,23]. This ability has
been ascribed to DHA and EPA to varying degrees depending on the
nature of the cell. Any reduction in the incorporation of cholesterol
into the membrane is known to cause dissolution of these rafts.
Nuclear factor-κB upon activation is a potent transcription factor
for several inflammatory cytokines; cycloxygenase (COX)-2, adhesion
molecules and nitric oxide synthase. Upon activation by bacterial
endotoxins, oxidative stress, UV light or inflammatory cytokines, it
moves from the cytosol to the nucleus to enhance production of pro-
inflammatory cytokines. Several studies have shown that EPA and
DHA inhibit this inflammatory action in monocytes [24], dendritic
cells [19], macrophages [25] and endothelial cells [26]. They inhibit
monocyte NF-κB and consequently modulate transcription of TNF-α,
[22] (which plays a central role in inflammation) this influences the
other factors to indirectly control fatty and triacyl glycerol metabolism.
The PPARs are transcription factors which regulate gene expression by
binding to retinoic-X-receptors, which are bound by the ligand; 6 cis-
retinoic acid [27]. The genes coding for several enzymes involved in β-
oxidation are regulated by the PPAR-α isoform, predominantly found
in the liver. PPAR-γ is found in inflammatory cells and adipocytes and
is involved in increasing insulin sensitivity and regulating production
of inflammatory cytokines [28]. PPARs are activated by PUFAs,
especially DHA to cause decreased production of IL-6 and TNF-α as
well as effects its metabolic role on adipocytes [29]. This is proposed to
be the mechanism underlying the effect of omega-3 PUFAs in
reducing inflammation and plasma glycerol and improving insulin
sensitivity in diabetics.
Other effects of the variations in the lipid membrane are mediated
via the availability of arachidonic acid, an important substrate in the
production of very important bio-active lipid end products -
prostaglandins, thromboxanes and leukotrienes. These eicosanoids are
known mediators of inflammation causing, platelet aggregation,
smooth muscle contraction and vaso-dilatation. Intake of long chain
fatty acids (DHA and EPA) have been observed to cause decrease in
the production of these pro-inflammatory eicosanoids from
arachidonic acid as well as production of weaker or less inflammatory
analogues – prostaglandin E3 and thromboxanes A3 [30]. Recent
studies have shown that EPA and DHA are also substrates in complex
biosynthetic pathways that give rise to anti-inflammatory mediators
known as resolvins, protectins/neuroprotectins and maresins [31-33].
These mediators also take part in immuno-modulation and are
currently being hypothesized to be the major pathway through which
polyunsaturated fatty acids carry out their anti-inflammatory actions.
The omega 3 fatty acids bind to G-protein coupled receptors;
GPR40 and GPR120 are found on Adipocytes and inflammatory cells
[34]. The GPR 120 acts via its agonist, GW9508 to inhibit response of
macrophages to endotoxins [35]. This is achieved by activating the
inhibitory subunit (IκB) of NF-κB, and thereby inhibiting production
of TNF-α and IL-6. DHA and EPA are known to activate the genes for
GPR120, and their anti-inflammatory effects are to some extent
dependent on this pathway. Previous studies have shown that the anti-
inflammatory effects of DHA, was absent in GPR120 knockdown cells,
[27] further substantiating this assertion. This implies that the
inhibitory effects of DHA on NF-κB, most likely occurred via the
GPR120 pathway. However, both pathways may be involved in varying
degrees in different types of cells.
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Alteration in Membrane Lipids in Sickle Cell Disease
In mammalian cells this peculiar distribution of the membrane
lipids is of utmost importance in the maintenance of its integrity. The
red cells in their journey through areas of high oxygen tension are
particularly susceptible to the development of reactive oxygen species
[36,37]. Membrane damage due to increased oxidant stress as a result
of formation of oxygen free radicals and outstripping of the anti-
oxidant mechanisms is the main mechanisms of membrane damage in
SC. Intravascular haemolysis of sickle red cells also release haeme
protein and the enzyme arginase which mops up nitrous oxide and
arginine , respectively. This produces further oxidative stress, resulting
in production of more oxygen free radicals. These reactive oxygen
species disrupt the apolar acyl chains of the membrane phospholipids
and thereby making close-packing of the lipids impossible [29]. These
oxidized portions are usually removed by the phospholipases via a de-
acylation process and replaced by selective uptake from plasma lipids
in an ATP-dependent process called re-acylation. Inability to initiate
this repair process leads to excessive exposure of PS on the outer leaf of
the membrane. This exposure in platelets has been noted to be the
initial step in activation of the coagulation cascade [38] and its
occurrence in red cells lead to removal by macrophages as well as
interactions with other cells and vascular endothelium [5]. In
haemoglobinopathies the altered haemoglobin produces added
oxidant stress on the anti-oxidant system, as well as the repair process
of the membrane phospholipid layer[39,40].
Homozygous S individuals have been shown to have a reduced
capacity to handle oxidative stress. This is coupled with their enhanced
propensity of the red cell environment to generate oxygen free radical
due to its iron content and passage through regions of high oxygen
tension, as it traverses the vasculature. There is also an observed
reduction in the activity of plasma as well as membrane bound anti-
oxidants notably, plasma retinol, α-tocopherol and β-carotene and the
red cell Cu/Zn-superoxide dismutase and Se-glutathione peroxidase
[41]. The changes in these anti-oxidants have also been observed to
correlate with the concentration of the fatty acids DHA and EPA [36],
it has not yet become clear which is the cause or effect of the other.
However, it has been proposed that the increased generation of oxygen
free radicals leads to peroxidation of the more susceptible lipids- n-5
and n-6 fatty acids, and their subsequent depletion. It will however
need to be demonstrated that an increase in the antioxidant levels will
lead to a subsequent increase in omega 3 fatty acid levels.
Background Inflammation in Sickle Cell
Sickle cell patients with a high leukocyte counts have higher
predisposition to develop vaso-occlusive crises as well as several other
chronic complications of sickle cell disease. High levels of pro-
inflammatory cytokines have been observed in these patients even
while in steady state [42-44]. There’s increasing evidence of the over-
expression of the platelet selectin and its ligand (PSGL-1 or CD162),
leukocyte selectin (CD62), β2 integrin and platelet endothelial cell
adhesion molecule-1[6]. The vascular endothelium is also activated
with increased expression of inter-cellular adhesion molecule-1
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). This
background state of smoldering inflammation persists, though on a
lower scale in sickle cell patients in steady state. The initial contact and
rolling of the leukocytes on the endothelium is mediated via CD62L,
while the firmer attachment and diapedesis are mediated by β
integrins and CD31 (PECAM-1 platelet endothelial cell adhesion
molecule). These leukocytes then bind to each other and to the
platelets, red cells and reticulocytes to form larger aggregates, capable
of occluding vascular lumen. This is similar to the initial steps
observed in acute inflammatory processes and also involves
endothelial activation via TNF-α and interleukin-1β, released by
monocytes. Periodic exacerbation of these events occur as vaso-
occlusive crisis when external stimuli, like infections or physiologic
stress, cause greater amounts inflammatory cytokines to be released by
activated leukocytes.
These cellular adhesion molecules and their ligands occur as trans-
membrane proteins and receptors, and their concentrations as well as
activity are most likely affected by the lipid composition of the
membrane. A large community-based study has shown an inverse
relationship between the level of inflammatory biomarkers (notably
IL-6, TNF receptor, ICAM-1 and P-selectin) and the blood EPA and
DHA levels [45,46]. Drugs like hydroxyurea (HU) have been found to
cause improvement even in patients in whom there was no significant
change in their haemoglobin F levels. Apart from reducing the
neutrophil count (and thereby depleting the overall number of
inflammatory cells and ligands available), it has been found to also
reduce expression of adhesion molecules by reticulocytes [47] and
inhibit the translocation of PS to the outer membrane leaf of the red
cell [48].
Possible genetic variations underlying observed changes in lipid
metabolism and their possible influence on disease phenotype.
There are peculiar differences which exist in the genome of
minority of individuals; these variations may lead to alterations in
quantity or activity of certain enzymes. These small scale genetic
variations include; single, double or multi-nucleotide polymorphisms
(SNP), as well as microindels. Microindels are additions or deletions of
extra nucleotides as well as occurrence of repetitions of 1 to 50
nucleotides, or combinations of both within the sequence. SNPs are
single base changes in the DNA sequence, seen in less than 1% of
individuals, which occur at an approximate frequency of 1 in 1000kb
[49] and may or may not be of clinical significance. These mutations
may occur in the coding region of genes encoding the fatty acid
desaturases or inflammatory cytokines and thereby confer some
phenotypic differences in terms of disease severity. Previous studies
have observed that SNPs and microindels have been implicated in
drug metabolism via their encoding gene- CYP2D6 with loss of
enzyme activity and slow metabolism [50,51]. Alterations in the FADS
enzyme genes are associated with the variations in the activity of these
enzymes [52,53] as well as the K-ras gene in some other patient
groups. Polymorphism in the genes coding for the FADS enzymes
have been discovered in genome wide association studies by Guan et
al. [54].
The FADs enzymes as well as phospholipase-A 2, play a pivotal role
in the production of the anti-inflammatory omega-3 fatty acids and
pro-inflammatory omega-6 fatty acids. Previous studies have shown
low activity of the FADS enzymes as well as omega-3 fatty acids in
sickle cell patients with severe disease. Meta-analysis of genes coding
for the Omega-6 fatty acids have also revealed that gene loci in other
chromosomes as well as distant SNPs may also affect the level and
activity of this enzyme [54]. Modifications and changes in the genes
coding for these enzymes will lead to loss of FADS enzyme activity or
quantity and invariably lead to increased production of IL-6 and TNF-
α, with subsequent worsening of the clinical features of the disease. We
hypothesize this as a possible explanation for the variations in the
phenotypic manifestations observed in sickle cell disease.
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Future Therapeutic Implications
Therapeutic targets have so far concentrated on the red cell-induced
vaso-occlusion and the haemolysis associated with the disease. This
has included attempts at improving hydration, ameliorating anti-
oxidant effects, increasing synthesis of HbF, replenishing plasma
arginine and improving red cell rheology. This section will however
focus on the possible prospective anti-inflammatory and fatty acid
metabolic options.
Omega-3 fatty acids
The omega-3 fatty acids play a pivotal role in the synthesis of less
inflammatory end products of the cycloxygenase pathway, but more
importantly suppress transcriptions of the genes of potent cytokines,
which mediate inflammation. This has been shown by several studies
in past in different patient groups, including SC [6] and diabetes, [55]
where they have been noted to induce amelioration of the symptoms
and improve well-being [56]. Dietary DHA and EPA, after
incorporation into the cell membrane, have also been shown in
previous studies to increase membrane fluidity and thus affect the
activity of the transmembrane proteins [12]. These are natural
products with little or no side effects, which given at certain doses,
positively influence metabolic pathways to favor reduced
inflammation, and consequently reduce disease severity. It must
always be remembered that inflammation is an innate defensive
mechanism and that it’s prolonged and sustained suppression, may
likely lead to some untoward effects. However the PUFAs as opposed
to the saturated FAs competitively bind to the Toll-like receptor 4,
through which it influences the transcription of NF-κ, and
consequently the COX-2 pathway, while the COX-1 pathway remains
relatively untouched [25]. In this way the most beneficial
inflammatory proteins and cytokines are to a large extent preserved.
The therapeutic threshold for each disease entity, as well as the ‘ceiling
dose’, beyond which severe adverse effects occur, has not yet been
adequately established. The ratio of omega-3 to omega-6 fatty acids
has also been observed to be of importance, since the excess of
omega-6 FAs favors the increased inflammation, insulin resistance and
macrophage infiltration[57]. Future research will most likely focus on
the synthesizing omega-3 fatty acid analogues and mixtures of various
PUFAs in order to achieve an effective dosing and metabolic
equilibrium.
Fatty Acid Desaturases and their encoding genes
These enzymes occur as the rate-limiting enzymes in the
production of the omega-3 fatty acids [58]. Increase in the production
of these fatty acids can also be achieved by increasing the FADS
enzyme activity or alternatively targeting their coding genes or
transcription factors [59]. The FADS1 and 2 enzymes are encoded by
exon 13 on chromosome 11q12.2-13.1for FADS1 and exon 14 on
chromosome 11q12.2, for FADS 2. Alterations in the form of
polymorphisms affecting these genes will affect their transcription
[52,53] and may be utilized to obtain an increase in production of
PUFAs. Also these areas may be targeted by plasmids containing
specific desired sequences which are capable of converting severe to
mild disease phenotypes.
Hydroxyurea and its analogues
Majority of the effects of HU on sickle cell disease is carried out via
its ability to reduce neutrophil count, increase HbF levels [60] and
reduce expression of cellular adhesion molecules[48,61].
Hydroxycarbamide also reduces the exposure of phosphatidyl serine
on the surface of platelets and red cells [48]. It has been observed that
HU does not cause an increase in HbF in all SCA patients, [62]and
does not completely protect against end organ damage [63]. Previous
research has also shown that HU mobilizes arachidonic acid from the
inner leaflet of the red cell membrane via its action on COX-2 and
cytoplasmic PLA-2 [64]. The eicosanoids DHA which is generated as a
result of this process is thought to play a part in the therapeutic
improvement seen in patients on HU. However the observation of a
reduction in fertility and alterations in sex hormones after 6 months of
therapy raises some concerns [65]. There arises the need to increase
efforts to produce a safer analogue of this very important molecule,
which may also be used in combination with drugs acting via other
pathways at less toxic doses.
Inhibition of adhesion molecules
Several adhesion molecules are being targeted in on-going trials.
The selectin inhibitors, Rivipansel and low molecular weight heparin
both act by inhibiting platelet, leukocyte and endothelial adhesion[46].
HU to a large extent also diminishes the cellular and endothelial
adhesion molecules by reducing the total number of white cells
available for adhesion [66]. Omega 3 fatty acids on the other hand
suppress the expression of the adhesion molecules β2- integrin
(CD-11b) and L-selectin (CD62L) in monocytes and granulocytes [6].
Intravenous gamma globulins as well as β3-integrin inhibitors are also
being tested [63]. These molecules are quite appropriate for both
prevention and treatment of end organ damage, in some cases.
However the search for a treatment of the most prevalent form of
crisis- the acute vaso-occlusive (bone pain) still remains elusive.
Emergency therapeutic drugs are still required which should be
capable of adequately aborting acute vaso-occlusion.
Resolvins/Protectins pathway activators
The resolvins, protectins and maresins are end product of the
metabolism of DHA and to a lesser extent EPA, via complex
biosynthetic pathways. They seem to play an important role in
suppressing inflammation and have been hypothesized to be the major
pathway through which n-3 fatty acids achieve these ends [67]. They
also play a role in modulating immune functions via their direct effect
on gene expression, targeting genes coding for cytokines, cyclo-
oxygenase, nitric oxide synthetase and metalloproteinases [20,68].
Therefore these mediators or their analogues can be given directly, as a
form of more specific therapeutic targeting, to achieve these desirable
ends.
Targeting genes for transcription factors in the
inflammatory pathway
Down-regulation of the transcription factor NF-κB has been noted
repeatedly to be responsible for majority of the actions of most
important prospective molecules in trial. Synthetic products targeting
this transcription factor can be developed and tried in the clinical
setting. Gene therapy has been on the lime-light for some years now,
but newer target genes should be explored. Ex-vivo manipulation of
autologous haemopoietic stem cells have also been tried, especially for
patients who do not have a matched donor [69]. Newer and safer viral
vectors have also been developed to overcome the occurrence of
genotoxicity. The beta globin gene chain in erythropoietic stem cells
had been used in the past, but current and future researches are
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focusing on the pluripotent stem cells [70]. It may also be helpful
target the inflammatory genes if these makes transfection and uptake
more tolerable, as this may serve to ameliorate disease severity.
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